Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 10.7% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in gene editing technologies. The company is known for its unique presence in the biotechnology industry.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 10.7% on Feb 26, 2026 20:57

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Fourth Quarter and Full-Year 2025 Financial Results Call

Intellia Therapeutics has scheduled its fourth quarter and full-year 2025 financial results conference call and webcast. The event is set to take place on February 26, 2026, at 8:00 AM EST to discuss the company's financial performance and operational highlights.

https://ir.intelliatx.com/events/event-details/intellia-therapeutics-fourth-quarter-and-full-year-2025-financial-results-call

Intellia Therapeutics (NTLA) Set to Announce Q4 Earnings

Intellia Therapeutics (NTLA) is scheduled to release its Q4 earnings on February 26th, with analysts predicting a -$0.96 EPS and $12.17 million in revenue, a slight decline year-over-year. Despite financial challenges like negative profitability and an Altman Z-Score in the distress zone, the company shows strong liquidity and its gene-editing drug clinical hold has been lifted. The article highlights Intellia's speculative investment profile due to its innovative but high-volatility biotechnology operations.

https://www.gurufocus.com/news/8651891/intellia-therapeutics-ntla-set-to-announce-q4-earnings

Intellia Therapeutics to Announce Q4 Earnings on February 26

Intellia Therapeutics is scheduled to release its Q4 2023 earnings on February 26 before market open, with analysts forecasting an EPS of -$0.96 and revenue of $12.17 million, representing a 5.7% year-over-year decrease. Despite a cautious market sentiment due to gene editing platform risks, recent lifting of a clinical hold on its gene editing drug by the FDA has positively impacted stock performance. The company's future competitiveness may be enhanced by effective leveraging of new FDA guidance for rare disease pharmaceuticals.

https://intellectia.ai/news/stock/intellia-therapeutics-to-announce-q4-earnings-on-february-26

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Intellia Therapeutics, Inc. announced its management will participate in three upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference. The company, a clinical-stage gene editing firm, will host fireside chats at two of these events, which will be webcast live. Replays will be available on their website for 90 days.

https://www.globenewswire.com/news-release/2026/02/24/3243528/0/en/intellia-therapeutics-to-participate-in-upcoming-investor-conferences.html

How to watch Intellia’s March investor talks at three healthcare conferences

Intellia Therapeutics (Nasdaq: NTLA) announced its participation in three investor conferences in early March 2026: TD Cowen on March 3, Leerink Global Healthcare on March 9, and Barclays Global Healthcare on March 10. The fireside chats on March 3 and March 9 will be webcast live and replays will be available for approximately 90 days on the company's website. Following the news release, NTLA's stock gained 3.19%.

https://www.stocktitan.net/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-5g7878rzxe2g.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

Gasoline ($GASOLINE) Commodity Forecast: Up 14.6% Today

XRP ($XRP) Crypto Forecast: Down 5.3% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 10.7% Today

IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 5.2% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Up 7.9% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.1% Today

MGM Resorts International ($MGM) Stock Forecast: Up 6.4% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Up 5.2% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Up 7.0% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

05.01.2026 - NTLA Stock was down 6.8%

• While the FDA lifted the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis, the stock did not respond positively.
• Despite analysts raising price targets and institutional investors expressing optimism, the stock continued its bearish movement.
• Market reaction may have been influenced by ongoing concerns about a separate clinical hold on the cardiomyopathy study, overshadowing progress in the ATTRv-PN trial.
• Conflicting price targets provided by Baird and H.C. Wainwright possibly introduced uncertainty among investors, contributing to the stock's decline.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

04.01.2026 - NTLA Stock was down 5.7%

• The FDA lifting the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) was initially seen as a positive development, but the market reacted negatively, causing a 12.6% drop in the stock price.
• Despite the regulatory hurdle being cleared, investors may be concerned about the ongoing hold on the MAGNITUDE cardiomyopathy trial, leading to uncertainty about the company's future pipeline.
• Analysts providing varied ratings and decreased price targets could also contribute to the bearish sentiment, as the market digests the implications of the FDA decision and assesses the company's overall financial health and growth prospects.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

30.00.2026 - NTLA Stock was down 7.6%

• The FDA's decision to lift the clinical hold on Intellia's Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) resulted in a temporary boost in the stock price.
• However, the ongoing hold on the MAGNITUDE trial for cardiomyopathy patients, attributed to severe liver-related side effects, raised uncertainties and potential concerns among investors, contributing to the recent bearish trend.
• Despite the positive development of trial resumptions, persistent safety concerns and regulatory scrutiny surrounding Intellia's gene therapy programs likely influenced investor sentiment, leading to the bearish market activity.
• The diverse analyst ratings and the decrease in the average price target may have also impacted the downward movement, reflecting differing perspectives on the company's future despite its strong financial performance.

30.00.2026 - NTLA Stock was down 6.9%

• The FDA lifted a clinical hold on one of Intellia's late-stage gene therapy trials for hereditary transthyretin amyloidosis, allowing the company to resume patient enrollment. This news initially resulted in a 10% rise in shares.
• Despite the positive development regarding the lifted clinical hold, the bearish movement may be linked to the continued hold on another trial for ATTR-CM due to severe liver-related side effects, including a patient's death.
• Intellia's financial performance remains solid, with revenue growth and strong ratios. However, market sentiment could have been affected by uncertainties related to the paused trial and the necessity for new risk mitigation measures.
• Analysts have provided diverse ratings for Intellia Therapeutics, with some lowering price targets. This may be indicative of concerns about the regulatory obstacles facing the company, despite the promising nature of its gene-editing therapies.